uniQure (NASDAQ:QURE) Price Target Raised to $32.00 at Stifel Nicolaus

uniQure (NASDAQ:QURE) had its price target increased by equities researchers at Stifel Nicolaus from $12.00 to $32.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Stifel Nicolaus’ target price indicates a potential upside of 94.41% from the stock’s previous close.

Several other research firms also recently weighed in on QURE. Royal Bank of Canada increased their price target on shares of uniQure from $14.00 to $20.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 11th. Guggenheim reaffirmed a “buy” rating on shares of uniQure in a research report on Wednesday, December 11th. Cantor Fitzgerald lifted their target price on shares of uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a research note on Tuesday, December 10th. Raymond James raised shares of uniQure from an “outperform” rating to a “strong-buy” rating and increased their price objective for the company from $20.00 to $52.00 in a report on Tuesday, December 10th. Finally, StockNews.com upgraded shares of uniQure to a “sell” rating in a research report on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $32.13.

uniQure Price Performance

Shares of NASDAQ:QURE opened at $16.46 on Monday. The company’s fifty day moving average is $7.28 and its 200 day moving average is $6.47. uniQure has a 52 week low of $3.73 and a 52 week high of $17.71. The stock has a market cap of $802.31 million, a PE ratio of -3.27 and a beta of 0.89. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.21. The business had revenue of $2.29 million during the quarter, compared to the consensus estimate of $2.73 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. Research analysts anticipate that uniQure will post -3.82 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction on Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the completion of the sale, the chief executive officer now directly owns 597,915 shares of the company’s stock, valued at approximately $4,562,091.45. The trade was a 0.57 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 4.74% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in QURE. RTW Investments LP acquired a new position in uniQure in the third quarter valued at $49,000. China Universal Asset Management Co. Ltd. grew its position in shares of uniQure by 57.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 3,663 shares during the last quarter. Atria Investments Inc acquired a new position in shares of uniQure in the 3rd quarter valued at $53,000. Quarry LP purchased a new position in uniQure during the 3rd quarter worth $58,000. Finally, Vanguard Personalized Indexing Management LLC boosted its stake in shares of uniQure by 21.0% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after buying an additional 2,306 shares during the period. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.